Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Trial Details

NCT ID

NCT05694312

Phase

PHASE2

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Ibrutinib 420 mg

Locations (sample)

• Florence, Italy|43.77925,11.24626
• Novara, Italy|45.44694,8.62118
• Torino, Italy|44.88856,11.99138

Key Eligibility Criteria

• Diagnosis of CLL/small lymphocytic lymphoma (SLL) or CLL-like monoclonal B-cell lymphocytosis (MBL) according to IWCLL guidelines.
• Patients \>18 years old
• Active AIHA (wAIHA or CAD) that i) is relapsed after previous treatment with corticosteroids (with or without rituximab), or ii) is steroid-resista…
• Eligibility of patients with DAT-negative active AIHA should be confirmed by the Principal Investigator and co-Principal Investigator for the trial.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.